Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INJECTAPAP vs CIALIS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.
Management of mild to moderate pain,Reduction of fever
Treatment of erectile dysfunction,Treatment of benign prostatic hyperplasia,Treatment of pulmonary arterial hypertension (as Adcirca)
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
The terminal elimination half-life of tadalafil is approximately 17.5 hours in healthy subjects, which supports once-daily dosing for erectile dysfunction and once-daily use for benign prostatic hyperplasia. This long half-life distinguishes it from other PDE5 inhibitors.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily hepatic via CYP3A4; minor pathways include CYP2C9 and glucuronidation.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Following oral administration, tadalafil is predominantly eliminated by hepatic metabolism. The metabolites are excreted mainly in feces (approximately 61% of the dose) and to a lesser extent in urine (approximately 36% of the dose). No unchanged parent drug is detected in urine.
10-25% bound to albumin at therapeutic concentrations.
Tadalafil is 94% bound to plasma proteins, primarily to albumin. The protein binding is independent of drug concentration over a wide range.
0.8-1.0 L/kg; suggests distribution into total body water.
The apparent volume of distribution (Vd/F) is approximately 63 L (or roughly 0.9 L/kg for a 70 kg individual), indicating distribution into tissues beyond the vascular space, including the penis and other target organs.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Absolute oral bioavailability of tadalafil has not been formally determined; however, the drug is well absorbed after oral administration, with peak plasma concentrations reached in 0.5 to 6 hours (median 2 hours). Food does not affect the extent of absorption (AUC), though it may delay the rate (Tmax) by about 1–2 hours.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Cr Cl 30-50 m L/min: 5 mg once daily (max) for daily use; as-needed dosing: 10 mg not to exceed once every 48 hours. Cr Cl <30 m L/min: not recommended. Hemodialysis: not studied.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Child-Pugh A and B: no dose adjustment necessary for as-needed dosing; daily use: caution, start at 5 mg once daily. Child-Pugh C: not recommended.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Not indicated for pediatric patients under 18 years.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
No dose adjustment required solely based on age; consider renal function and concomitant medications.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
None
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Risk of hypotension with vasodilators or alpha-blockers,Contraindicated with nitrates due to severe hypotension risk,Patients with left ventricular outflow obstruction (e.g., aortic stenosis) should avoid use,Caution in patients with hypotension, severe hepatic impairment, or end-stage renal disease,Risk of priapism: advise immediate medical attention for erections lasting >4 hours,Decreased visual or hearing ability requiring discontinuation
Hypersensitivity to acetaminophen or any component of the formulation
Concomitant use of nitrates (any form) or riociguat,Hypersensitivity to tadalafil,Concomitant use with alpha-blockers (except for BPH with appropriate dosing)
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Avoid high-fat meals prior to dosing as they may delay absorption and reduce peak plasma concentration. Avoid large quantities of grapefruit juice (more than 1 liter per day) as it may increase tadalafil exposure via CYP3A4 inhibition.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
FDA Pregnancy Category B. Animal studies show no evidence of teratogenicity or embryotoxicity. No adequate, well-controlled studies in pregnant women. Risk cannot be ruled out; use only if clearly needed.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Excretion in human milk unknown. Not recommended for use in nursing mothers. M/P ratio not determined.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
No specific dose adjustments studied in pregnancy. Use lowest effective dose if necessary, with caution for increased plasma volume and renal clearance potentially altering pharmacokinetics.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Tadalafil (Cialis) has a 17.5-hour half-life allowing once-daily dosing for ED or daily for BPH/LUTS. Avoid use with nitrates; may cause prolonged erection. Onset of action is 30-60 minutes, and effect may last up to 36 hours. Use with caution in patients with left ventricular outflow obstruction or severe hepatic impairment.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
Do not take tadalafil if you take any form of nitrate medication (e.g., nitroglycerin) for chest pain.,Seek immediate medical help if you have an erection lasting more than 4 hours.,Avoid alcohol consumption as it may increase the risk of dizziness and low blood pressure.,Take tadalafil at least 30 minutes before sexual activity; effect can last up to 36 hours.,For daily use, take at the same time each day without regard to timing of sexual activity.,Grapefruit and grapefruit juice may increase tadalafil levels; avoid large amounts.,Inform your doctor of all medications you take, especially alpha-blockers, antihypertensives, and antifungal or antibiotic drugs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INJECTAPAP vs CIALIS, answered by our medical review team.
INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. CIALIS is a PDE5 Inhibitor that works by Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INJECTAPAP and CIALIS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of CIALIS is: Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INJECTAPAP and CIALIS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. CIALIS is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of teratogenicity or embryotoxicity. No adequate, well-controlled studies in pregnant women. Risk cannot be ruled out; use. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.